Caribou Biosciences annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Caribou Biosciences Stock-Based Compensation Growth & History (CRBU)
Caribou Biosciences's stock-based compensation was $12.7M for fiscal 2025.
View full Caribou Biosciences company overviewCaribou Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.7M | −$4.0M | −24.10% |
| 2024 | 2024-12-31 | $16.7M | $3.0M | +21.50% |
| 2023 | 2023-12-31 | $13.8M | $2.0M | +17.36% |
| 2022 | 2022-12-31 | $11.7M | $8.3M | +239.69% |
| 2021 | 2021-12-31 | $3.4M | $2.4M | +244.21% |
| 2020 | 2020-12-31 | $1.0M | −$232,000 | −18.80% |
| 2019 | 2019-12-31 | $1.2M | — | — |
Caribou Biosciences quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.5M | −$652,000 | −20.84% |
| Q1 2026 | 2026-03-31 | $2.4M | −$1.5M | −39.28% |
| Q4 2025 | 2025-12-31 | $2.7M | −$1.2M | −29.99% |
| Q3 2025 | 2025-09-30 | $2.9M | −$1.1M | −27.97% |
| Q2 2025 | 2025-06-30 | $3.1M | −$1.6M | −33.96% |
| Q1 2025 | 2025-03-31 | $3.9M | −$106,000 | −2.66% |
| Q4 2024 | 2024-12-31 | $3.9M | $355,000 | +9.98% |
| Q3 2024 | 2024-09-30 | $4.1M | $591,000 | +16.99% |
| Q2 2024 | 2024-06-30 | $4.7M | $1.2M | +32.16% |
| Q1 2024 | 2024-03-31 | $4.0M | $857,000 | +27.37% |
| Q4 2023 | 2023-12-31 | $3.6M | $455,000 | +14.67% |
| Q3 2023 | 2023-09-30 | $3.5M | $805,000 | +30.12% |
| Q2 2023 | 2023-06-30 | $3.6M | $667,000 | +22.86% |
| Q1 2023 | 2023-03-31 | $3.1M | $107,000 | +3.54% |
| Q4 2022 | 2022-12-31 | $3.1M | $1.5M | +96.51% |
| Q3 2022 | 2022-09-30 | $2.7M | $1.7M | +185.88% |
| Q2 2022 | 2022-06-30 | $2.9M | $2.3M | +392.07% |
| Q1 2022 | 2022-03-31 | $3.0M | $2.7M | +781.63% |
| Q4 2021 | 2021-12-31 | $1.6M | — | — |
| Q3 2021 | 2021-09-30 | $935,000 | $687,000 | +277.02% |
| Q2 2021 | 2021-06-30 | $593,000 | $307,000 | +107.34% |
| Q1 2021 | 2021-03-31 | $343,000 | — | — |
| Q3 2020 | 2020-09-30 | $248,000 | — | — |
| Q2 2020 | 2020-06-30 | $286,000 | — | — |
Caribou Biosciences stock-based compensation trends
Over the last five fiscal years, Caribou Biosciences's stock-based compensation increased from $1.0M to $12.7M, a change of $11.7M. The latest reported quarter, Q2 2026, shows $2.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Caribou Biosciences source filings ↗